# Treatment Based on Molecular Profiling Diagnosis Carcinoma of Unknown Primary Site

> **NCT00737243** · PHASE2 · COMPLETED · sponsor: **SCRI Development Innovations, LLC** · enrollment: 289 (actual)

## Conditions studied

- Carcinoma

## Interventions

- **DRUG:** Paclitaxel
- **DRUG:** Carboplatin
- **DRUG:** Bevacizumab
- **DRUG:** Erlotinib
- **OTHER:** Treatment determined by physician

## Key facts

- **NCT ID:** NCT00737243
- **Lead sponsor:** SCRI Development Innovations, LLC
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-08
- **Primary completion:** 2012-11
- **Final completion:** 2012-12
- **Target enrollment:** 289 (ACTUAL)
- **Last updated:** 2016-08-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00737243

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00737243, "Treatment Based on Molecular Profiling Diagnosis Carcinoma of Unknown Primary Site". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00737243. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*